Form 4: Pfizer CEO Albert Bourla Reports Acquisition of Phantom Stock Units

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 19 phantom stock units through the company's Supplemental Savings Plan.

Summary

• Albert Bourla, Chairman and CEO of Pfizer Inc., filed a Form 4 with the SEC on July 1, 2024.
• The filing reports a transaction that occurred on June 28, 2024.
• Bourla acquired 19 phantom stock units through the Pfizer Supplemental Savings Plan (SSP).
• Each unit represents one phantom share of Pfizer common stock.
• The price of the derivative security is $27.98.
• Following the reported transaction, Bourla directly owns 669,291 shares.
• These units are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Sentiment

Score: 5

Explanation: This is a routine transaction filing, neither particularly positive nor negative. It reflects standard executive compensation practices.

Positives

• The acquisition of phantom stock units through the Supplemental Savings Plan aligns the CEO's interests with the long-term performance of the company.
• The ability to transfer the units into an alternative investment account provides flexibility for the reporting person.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the CEO's participation in the company's savings plan.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• It provides transparency into executive compensation.

Key Dates